Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer

Figures & data

Table 1 Comparison of EGFR Gene Mutation of Different Types of Lung Cancer (%)

Group	EGFR 19	EGFR 18	EGFR 21	EGFR 20	Gene Mutation
Adenocarcinoma group (n=201)	4 (1.99)	76 (37.81)	28 (13.93)	5 (2.49)	113 (56.22)
Non-small cell carcinoma group (n=101)	16 (15.84)	4 (3.96)	17 (16.83)	6 (5.94)	43 (42.57)
Squamous carcinoma group (n=28)	6 (21.43)	1 (3.57)	3 (10.71)	0 (0.00)	10 (35.71)
χ^2					8.815
P					0.012

Notes: χ² is chi-square test, and P is the probability that the original hypothesis is true. EGFR is epidermal growth factor receptor.

Table 2 Comparison of KRAS Gene Mutation of Different Types of Lung Cancer (%)

Group	KRAS E2	KRAS E3	KRAS E15	Gene Mutation
Adenocarcinoma group (n=201)	36 (17.91)	29 (14.43)	7 (3.48)	72 (35.82)
Non-small cell carcinoma group (n=101)	8 (7.92)	7 (6.93)	1 (0.99)	16 (15.84)
Squamous carcinoma group (n=28)	2 (7.14)	2 (7.14)	0 (0.00)	4 (14.29)
χ^2				16.815
P				0.000

Notes: χ² is chi-square test, and P is the probability that the original hypothesis is true. KRAS is Mouse sarcoma virus carcinoma.

Table 3 Comparison of BRAF Gene Mutation of Different Types of Lung Cancer (%)

Group	BRAF E15
Adenocarcinoma group (n=201)	10 (4.98)
Non-small cell carcinoma group (n=101)	5 (4.95)
Squamous carcinoma group (n=28)	1 (3.57)
χ^2	0.302
P	0.860

Notes: χ² is chi-square test, and P is the probability that the original hypothesis is true. BRAF is mouse sarcomatosis Toxic carcinogenic homologue.

Table 4 Expression Differences of PD-L1 in Patients with Different Types of Lung Cancer [N, (%)]

PD-L1	Adenocarcinoma Group (n=201)	Non-Small Cell Carcinoma Group (n=101)	Squamous Carcinoma Group (n=28)	χ^2	P
Negative	47 (23.39)	15 (14.85)	3 (10.71)	25.383	0.000
Weak	48 (23.89)	21 (20.79)	10 (35.71)
Moderate	76 (37.81)	25 (24.75)	9 (32.14)
Strong	30 (14.93)	40 (39.60)	6 (21.43)

Notes: χ² is chi-square test, and P is the probability that the original hypothesis is true. PD-L1 is Programmed death receptor-ligand 1.

Figure 1 PD-L1 respective immunohistochemical staining of different types of lung cancer-from left to right are negative, weak, moderate and strong expression. (A) Immunohistochemical staining was negative; (B) Immunohistochemical staining was weak positive; (C) Immunohistochemical staining showed moderate positive; (D) Immunohistochemical staining showed strong positive.